Clinical Trials Market Report 2026

The clinical trials market size has grown strongly in recent years. It will grow from $127.16 billion in 2025 to $135.51 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to growth of pharmaceutical r&d investment, expansion of global drug development pipelines, increasing prevalence of chronic diseases, establishment of regulatory clinical trial frameworks, rising outsourcing to contract research organizations.

The clinical trials market size is expected to see strong growth in the next few years. It will grow to $176.32 billion by 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to adoption of AI enabled clinical trial design, expansion of precision medicine based trials, growth of decentralized and virtual trials, increasing regulatory emphasis on real world evidence, rising demand for faster drug approval timelines. Major trends in the forecast period include increasing adoption of decentralized clinical trials enabled by digital platforms, rising use of ai driven patient recruitment and trial optimization, growth of real time remote patient monitoring in clinical studies, expansion of patient centric trial designs improving retention rates, increasing outsourcing of clinical trial functions to cros.

The increasing demand for new drug development is anticipated to drive the expansion of the clinical trials market in the forecast period. New drug development refers to the process of discovering, assessing, and introducing new pharmaceutical compounds into the market to address unmet medical needs. The rise in new drug development is fueled by the growing requirement for innovative therapies to treat chronic and complex diseases, resulting in increased research and testing activities. Clinical trials support the demand for new drug development by enabling systematic evaluation of drug safety, efficacy, and regulatory compliance across different trial phases. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, total pharmaceutical production in Europe accounted for €390.0 billion ($422,803 million) in 2023, up from €363.3 billion ($393,857 million) in 2022. Therefore, the increasing demand for new drug development is driving the expansion of the clinical trials market.

Leading companies operating in the clinical trials market are focusing on developing advanced solutions, such as integrated decentralized clinical trial (DCT) platforms, to improve patient accessibility, streamline trial operations, and enhance data collection efficiency. Decentralized clinical trial platforms refer to technology-driven systems that enable remote patient participation, virtual monitoring, and digital data capture, reducing the need for physical site visits and improving trial flexibility. For example, in June 2024, IQVIA, a US-based provider of advanced analytics, technology solutions, and clinical research services, launched One Home for Sites, a unified clinical trial technology platform designed to support decentralized and hybrid trials. The platform integrates various digital capabilities, including remote patient monitoring, telehealth, eConsent, and data collection tools, into a single interface, enabling seamless trial management, improving patient engagement, and accelerating clinical research outcomes.

In October 2025, Thermo Fisher Scientific Inc., a US-based life sciences and clinical research company, acquired Clario for up to $9.4 billion. Through this acquisition, Thermo Fisher intends to substantially enhance its clinical trial research and data management capabilities by integrating Clario’s advanced endpoint data solutions, thereby strengthening its end-to-end clinical development services and enabling more efficient, data-driven execution of clinical trials across global studies. Clario is a US-based clinical research technology company that provides services related to clinical trials.

Major companies operating in the clinical trials market are ICON plc, WuXi AppTec Co Ltd, Charles River Laboratories International Inc, Fortrea Holdings Inc, CMIC Holdings Co Ltd, EPS Holdings Inc, Medpace Holdings Inc, Pharmaron Beijing Co Ltd, Hangzhou Tigermed Consulting Co Ltd, ClinChoice Inc, Worldwide Clinical Trials Holdings Inc, Lambda Therapeutic Research Ltd, Syngene International Ltd, Altasciences Company Inc, KCR SA, Accutest Research Laboratories India Pvt Ltd, Rho Inc.

North America was the largest region in the clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clinical trials market includes revenues earned by entities by providing services such as patient recruitment and retention services, clinical monitoring services, pharmacovigilance and safety reporting, and medical writing and documentation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.